Investor Relations

Investor FAQs

Show All
What does Anika Therapeutics do?

Answer: Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair in the United States, Europe, and internationally. The Company is a leader in the viscosupplemention market with activities in multiple additional markets, including orthopedic and regenerative medicine, dermal products, surgical products, ophthalmic products and veterinary products. Anika's products are based on hyaluronic acid (HA) technology, a naturally occurring, biocompatible polymer found throughout the body, which acts to enhance joint function, to coat, protect, cushion and lubricate soft tissues, and to support skin structure and elasticity.

When was Anika founded?

Anika was founded in 1992.

What stock exchange is Anika traded on and what is its stock symbol?

Anika is traded on the Nasdaq Global Select Market under the symbol ANIK.

When does Anika's fiscal year end?

Anika’s fiscal year ends December 31.

What is Anika's competitive advantage?

With 20 years of experience in its field, Anika has many competitive strengths including:

- Unique expertise in efficiently manufacturing extremely pure, high molecular weight HA-based products with exceptional safety profiles in state-of-the-art manufacturing facility located at the company's headquarters.

- Viscosupplementation products contain highest concentration of non-animal sourced HA among competitors providing for maximum effectiveness at lower injectable volumes.

- Strong product pipeline will continue to allow the company to deliver new and improved products to the market.

- Strong brand recognition as a result of robust distribution network.

How can I obtain Anika's investor kit?

Please visit Anika’s Information Request page to receive an investor kit.

When is the next financial results release date?

Please click here for more information.

How can I receive a copy of Anika's financial statements?

Anika’s financial statements are available for viewing in the SEC Filings section of its investor relations website. To receive a hard copy of the Company’s financial statements, please visit the Information Request section of the site and complete the electronic form provided.

Who serves on Anika's management team?

For detailed information about Anika’s management team, click here.

Who serves on Anika's Board of Directors?

For detailed information about Anika’s Board of Directors, click here.

Does Anika pay a dividend on its common stock?

Anika has never declared a cash dividend on its common stock, nor does it presently have any plans to initiate a dividend program.

Does Anika have a direct stock repurchase program?

Anika does not have a direct stock purchase program, and presently does not anticipate establishing one.

Who should I contact with questions regarding my shares, transfer of my shares, replacement of a lost stock certificate or change in my address?

For detailed Contact information, please click here.

Who is Anika's independent accounting firm?

Deloitte LLP  is Anika’s accounting firm.

Who is Anika's outside legal counsel?

K&L Gates LLP serves as the Company’s outside general legal counsel.

What is Anika's CUSIP number?

Anika’s CUSIP number is 035255 10 8.

How can I contact Anika's investor relations?

Please contact:
Sylvia Cheung
Chief Financial Officer
781-457-9000
investorrelations@anikatherapeutics.com